Category Archives: Hepatitis C

Six Indian pharma companies get new licences to supply generic drugs

By Shreerupa Mitra-Jha, Firstpost | July 8, 2016 The UN-backed Medicines Patent Pool (MPP) announced on 7 July new generic manufacturing licensing, for antiretrovirals (ARVs) and direct acting anti-viral (DAA) for treating hepatitis C, with seven pharmaceutical companies, six of … Continue reading

Posted in Generics, Hepatitis C, Medicine Patent Pool, Uncategorized | Leave a comment

India allows Gilead to patent Hepatitis C drug. Here’s why it is cruel

By Vishakh Unnikrishnan, The CatchNews | May 14, 2016 Landing a blow to efforts to make vital drugs more affordable, the Indian Patent Office has granted the American pharmaceutical company Gilead a patent for sofosbuvir, which is used to treat … Continue reading

Posted in Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Leave a comment

Russia postpones compulsory licensing of imported drugs until December

Source: ThePharmaLetter | May 10, 2016 The Russian government has decided to postpone the introduction of a controversial scheme for the compulsory licensing of drugs imported into Russia, as proposed by some local drugmakers, reports The Pharma Letter’s local correspondent.

Posted in Compulsory Licensing, Hepatitis C, Uncategorized | Leave a comment

India Patent Office approves Gilead’s hepatitis C drug patent

By Deena Beasley, The Reuters | May 10, 2016 India has reversed course and granted approval to Gilead Sciences Inc’s patent for its hepatitis C drug Sovaldi, marking a setback for patient groups who said the move could stop affordable … Continue reading

Posted in Hepatitis C, Patent, Uncategorized | Leave a comment

Hepatitis C sufferer warns ‘hundreds of thousands will die’ if India changes patent law in trade deal

By South Asia correspondent James Bennett, ABC News | Apr 2, 2016 India, sometimes dubbed “pharmacy to the developing world”, is facing pressure to change strict patent laws as it negotiates a trade deal with Europe. That would make it easier … Continue reading

Posted in EU-India FTA, FTA, Generics, Hepatitis C, Indian Patent Law, Uncategorized | Leave a comment

The Low Cost of Universal Access

Generic treatments for HIV, viral hepatitis, and cancer can be affordably—and profitably—mass-produced for broad, unobstructed availability By Tracy Swan| TAGline Spring 2016 TAG talks with Andrew Hill, senior visiting research fellow in the University of Liverpool’s Department of Pharmacology, about his … Continue reading

Posted in Hepatitis C, Uncategorized | Leave a comment

Patent challenge hearing on Gilead hepatitis C drug sofosbuvir starts in India

‘Patent opposition’ seeks to ensure millions of people left out of Gilead licensing deals can access affordable generics   New Delhi/New York, 26 February 2016— In proceedings that could have major implications for millions of people waiting for affordable access … Continue reading

Posted in Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Leave a comment